ES2792574T3 - Formulación de Ceritinib - Google Patents

Formulación de Ceritinib Download PDF

Info

Publication number
ES2792574T3
ES2792574T3 ES15727470T ES15727470T ES2792574T3 ES 2792574 T3 ES2792574 T3 ES 2792574T3 ES 15727470 T ES15727470 T ES 15727470T ES 15727470 T ES15727470 T ES 15727470T ES 2792574 T3 ES2792574 T3 ES 2792574T3
Authority
ES
Spain
Prior art keywords
tablet
ceritinib
pharmaceutical composition
weight
granulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15727470T
Other languages
English (en)
Spanish (es)
Inventor
Sebastien Breulles
Simon Ensslin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2792574(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2792574T3 publication Critical patent/ES2792574T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
ES15727470T 2014-05-29 2015-05-27 Formulación de Ceritinib Active ES2792574T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29
PCT/IB2015/053966 WO2015181739A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Publications (1)

Publication Number Publication Date
ES2792574T3 true ES2792574T3 (es) 2020-11-11

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15727470T Active ES2792574T3 (es) 2014-05-29 2015-05-27 Formulación de Ceritinib

Country Status (27)

Country Link
US (4) US20170112834A1 (enExample)
EP (1) EP3148513B1 (enExample)
JP (3) JP6679578B2 (enExample)
KR (1) KR20170008239A (enExample)
CN (1) CN106456640B (enExample)
AR (1) AR100625A1 (enExample)
AU (3) AU2015265470A1 (enExample)
BR (1) BR112016027580A8 (enExample)
CA (1) CA2948291A1 (enExample)
CL (1) CL2016003047A1 (enExample)
DK (1) DK3148513T3 (enExample)
EA (1) EA036922B1 (enExample)
EC (1) ECSP16096826A (enExample)
ES (1) ES2792574T3 (enExample)
HU (1) HUE048950T2 (enExample)
IL (1) IL248835B (enExample)
MX (1) MX373624B (enExample)
PE (1) PE20170313A1 (enExample)
PH (1) PH12016502272A1 (enExample)
PL (1) PL3148513T3 (enExample)
PT (1) PT3148513T (enExample)
SG (1) SG11201609208UA (enExample)
SI (1) SI3148513T1 (enExample)
TN (1) TN2016000484A1 (enExample)
TW (1) TWI721946B (enExample)
UY (1) UY36140A (enExample)
WO (1) WO2015181739A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721946B (zh) 2014-05-29 2021-03-21 瑞士商諾華公司 色瑞替尼調配物
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
TW200803850A (en) * 2006-03-06 2008-01-16 Wyeth Corp Tablet formulations and processes
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
ES2377869T3 (es) 2008-09-04 2012-04-02 Cargill, Incorporated Fabricación de comprimidos de eritritol
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CN102480998B (zh) 2009-08-18 2016-05-25 卡吉尔公司 赤藓醇和异麦芽酮糖醇的压片
JP5596799B2 (ja) 2010-05-11 2014-09-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
CN103200828A (zh) 2010-09-07 2013-07-10 卡吉尔公司 固体化糖醇混合物
TWI721946B (zh) 2014-05-29 2021-03-21 瑞士商諾華公司 色瑞替尼調配物

Also Published As

Publication number Publication date
PH12016502272A1 (en) 2017-02-06
AU2019232937B2 (en) 2020-10-15
US20200009141A1 (en) 2020-01-09
CN106456640B (zh) 2021-05-14
US20210154194A1 (en) 2021-05-27
KR20170008239A (ko) 2017-01-23
MX2016015736A (es) 2017-03-16
MX373624B (es) 2020-05-22
BR112016027580A2 (pt) 2017-08-15
JP6679578B2 (ja) 2020-04-15
EA036922B1 (ru) 2021-01-15
IL248835A0 (en) 2017-01-31
EP3148513A1 (en) 2017-04-05
PL3148513T3 (pl) 2020-08-24
AU2019232937A1 (en) 2019-10-10
US11000523B2 (en) 2021-05-11
EA201692310A1 (ru) 2017-04-28
SI3148513T1 (sl) 2020-07-31
WO2015181739A1 (en) 2015-12-03
PT3148513T (pt) 2020-05-27
PE20170313A1 (es) 2017-04-18
JP2020114834A (ja) 2020-07-30
AU2018203007A1 (en) 2018-05-17
JP7084955B2 (ja) 2022-06-15
TN2016000484A1 (en) 2018-04-04
US12357630B2 (en) 2025-07-15
UY36140A (es) 2016-01-08
HUE048950T2 (hu) 2020-09-28
EP3148513B1 (en) 2020-02-26
IL248835B (en) 2020-05-31
DK3148513T3 (da) 2020-05-25
CA2948291A1 (en) 2015-12-03
SG11201609208UA (en) 2016-12-29
ECSP16096826A (es) 2018-04-30
CL2016003047A1 (es) 2017-04-07
TWI721946B (zh) 2021-03-21
BR112016027580A8 (pt) 2021-06-29
US20190022095A1 (en) 2019-01-24
TW201613580A (en) 2016-04-16
CN106456640A (zh) 2017-02-22
AU2018203007B2 (en) 2019-07-18
JP2017520619A (ja) 2017-07-27
JP2022078236A (ja) 2022-05-24
AR100625A1 (es) 2016-10-19
US20170112834A1 (en) 2017-04-27
AU2015265470A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
JP6588915B2 (ja) Ａｚｄ９２９１を含む医薬組成物
ES2645008T3 (es) Formas de dosificación sólida de bendamustina
ES2596554T3 (es) Comprimidos de acetato de ulipristal
US12357630B2 (en) Ceritinib formulation
ES2988678T3 (es) Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
KR20210147082A (ko) 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물
CN108096251B (zh) 一种吉非替尼药物组合物及其制备方法
ES2785398T3 (es) Composición farmacéutica que comprende Aripiprazol o sal del mismo
HK1229715B (en) Ceritinib formulation
HK1229715A1 (en) Ceritinib formulation
EP3251669B1 (en) Solid composition of pyrrole carboxamide
HK1228245B (en) Pharmaceutical compositions comprising azd9291